Literature DB >> 28035676

New old drug(s) for spinocerebellar ataxias.

Visou Ady1, Alanna J Watt1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28035676      PMCID： PMC5199732          DOI： 10.1113/JP273149

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  13 in total

1.  Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

Authors:  Raphael Hourez; Laurent Servais; David Orduz; David Gall; Isabelle Millard; Alban de Kerchove d'Exaerde; Guy Cheron; Harry T Orr; Massimo Pandolfo; Serge N Schiffmann
Journal:  J Neurosci       Date:  2011-08-17       Impact factor: 6.167

2.  GABA(B) receptor activation enhances mGluR-mediated responses at cerebellar excitatory synapses.

Authors:  M Hirono; T Yoshioka; S Konishi
Journal:  Nat Neurosci       Date:  2001-12       Impact factor: 24.884

Review 3.  Cellular and circuit mechanisms underlying spinocerebellar ataxias.

Authors:  Pratap Meera; Stefan M Pulst; Thomas S Otis
Journal:  J Physiol       Date:  2016-06-12       Impact factor: 5.182

4.  Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice.

Authors:  Heliane G Serra; Courtney E Byam; Jeffrey D Lande; Susan K Tousey; Huda Y Zoghbi; Harry T Orr
Journal:  Hum Mol Genet       Date:  2004-08-18       Impact factor: 6.150

Review 5.  Are Type 1 metabotropic glutamate receptors a viable therapeutic target for the treatment of cerebellar ataxia?

Authors:  Emmet M Power; Natalya A English; Ruth M Empson
Journal:  J Physiol       Date:  2016-02-24       Impact factor: 5.182

6.  Prolonged Type 1 Metabotropic Glutamate Receptor Dependent Synaptic Signaling Contributes to Spino-Cerebellar Ataxia Type 1.

Authors:  Emmet M Power; Adrienne Morales; Ruth M Empson
Journal:  J Neurosci       Date:  2016-05-04       Impact factor: 6.167

7.  Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.

Authors:  Serena Notartomaso; Cristina Zappulla; Francesca Biagioni; Milena Cannella; Domenico Bucci; Giada Mascio; Pamela Scarselli; Francesco Fazio; Filippo Weisz; Luana Lionetto; Maurizio Simmaco; Roberto Gradini; Giuseppe Battaglia; Michele Signore; Aldamaria Puliti; Ferdinando Nicoletti
Journal:  Mol Brain       Date:  2013-11-19       Impact factor: 4.041

8.  4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.

Authors:  Sriram Jayabal; Hui Ho Vanessa Chang; Kathleen E Cullen; Alanna J Watt
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

9.  Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.

Authors:  Kei Watase; Jennifer R Gatchel; Yaling Sun; Effat Emamian; Richard Atkinson; Ronald Richman; Hidehiro Mizusawa; Harry T Orr; Chad Shaw; Huda Y Zoghbi
Journal:  PLoS Med       Date:  2007-05       Impact factor: 11.069

10.  Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability.

Authors:  James M Dell'Orco; Aaron H Wasserman; Ravi Chopra; Melissa A C Ingram; Yuan-Shih Hu; Vikrant Singh; Heike Wulff; Puneet Opal; Harry T Orr; Vikram G Shakkottai
Journal:  J Neurosci       Date:  2015-08-12       Impact factor: 6.167
View more
  1 in total

1.  Altered synaptic and firing properties of cerebellar Purkinje cells in a mouse model of ARSACS.

Authors:  Visou Ady; Brenda Toscano-Márquez; Moushumi Nath; Philip K Chang; Jeanette Hui; Anna Cook; François Charron; Roxanne Larivière; Bernard Brais; R Anne McKinney; Alanna J Watt
Journal:  J Physiol       Date:  2018-07-19       Impact factor: 5.182
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.